Company Cyxone AB

Equities

CYXO

SE0007815428

Pharmaceuticals

Market Closed - Nasdaq Stockholm 11:05:53 2024-04-26 am EDT 5-day change 1st Jan Change
0.0928 SEK -4.33% Intraday chart for Cyxone AB +6.91% -7.57%

Business Summary

Cyxone AB is a Sweden-based company, which is primarily focused on specialty pharmaceuticals industry. The Company develops cyclotide drugs for autoimmune and other diseases. The Company's Product T20K is a compound to inhibit pro-inflammatory cytokines such as IL2 and effectively reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. The product T20K, through a pre-clinical program required for clinical studies in multiple sclerosis. The Company's cyclotides technology can be modified, while keeping the core cyclotide drug structure, to introduce a variety of pharmaceutical properties for selected diseases. The Company has acquired the cyclotide patent rights developed by the Medical University of Vienna and the University Medical Center of Freiburg.

Number of employees: 3

Managers

Managers TitleAgeSince
Chief Executive Officer 54 21-05-19
Founder 58 14-12-31
Director of Finance/CFO 63 23-06-14

Members of the board

Members of the board TitleAgeSince
Founder 58 14-12-31
Director/Board Member 58 14-12-31
Chairman 64 22-12-31
Chief Executive Officer 54 21-05-19
Director/Board Member 62 22-12-31
Director/Board Member 57 22-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 215,926,036 192,103,811 ( 88.97 %) 0 88.97 %

Company contact information

Cyxone AB

Hyllie Boulevard 34

215 32, Malmö

+46 7 08 88 21 72

http://www.cyxone.com
address Cyxone AB(CYXO)